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SUMMARY
Rolandic epilepsy (RE) and its atypical variants (atypical rolandic epilepsy, ARE) along
the spectrum of epilepsy–aphasia disorders are characterized by a strong but largely
unknown genetic basis. Two genes with a putative (ELP4) or a proven (SRPX2) function
in neuronal migration were postulated to confer susceptibility to parts of the disease
spectrum: the ELP4 gene to centrotemporal spikes and SRPX2 to ARE. To reexamine
these findings, we investigated a cohort of 280 patients of European ancestry with RE/
ARE for the etiological contribution of these genes and their close interaction part-
ners.We performed next-generation sequencing and single-nucleotide polymorphism
(SNP)–array based genotyping to screen for sequence and structural variants. In com-
parison to European controls we could not detect an enrichment of rare deleterious
variants of ELP4, SRPX2, or their interaction partners in affected individuals. The previ-
ously described functional p.N327S variant in the X chromosomal SRPX2 gene was
detected in two affected individuals (0.81%) and also in controls (0.26%), with some
preponderance of male patients. We did not detect an association of SNPs in the ELP4
gene with centrotemporal spikes as previously reported. In conclusion our data do not
support amajor role of ELP4 and SRPX2 in the etiology of RE/ARE.
KEYWORDS: Idiopathic focal childhood epilepsy, Mutation, Gene, CNV, Association,
SNP.
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BRIEFCOMMUNICATION
Rolandic epilepsy (RE), also known as benign childhood
epilepsy with centrotemporal spikes (BECTS), is the most
common childhood epilepsy syndrome. Although RE usu-
ally takes a benign course, there is an overlap with more
severe forms of idiopathic focal childhood epilepsies such
as atypical benign partial epilepsy (ABPE), Landau-Kleff-
ner syndrome (LKS), and the continuous spike-and-waves
during slow-wave sleep syndrome (CSWSS). These latter
syndromes are often referred to as atypical rolandic epilepsy
(ARE), and are considered to form together with RE the
spectrum of epilepsy–aphasia disorders (RE/ARE), with a
presumably shared strong genetic etiology.1,2
In most RE- and ARE-affected individuals, a complex,
polygenic inheritance with additional acquired factors
emerges as the most likely etiology.3 Yet, only a few chro-
mosomal loci and an even smaller number of individual
genes could be associated with the disease spectrum so far.
Pathologic variants of the glutamate receptor GRIN2A can
be detected in 7.5–20 % of RE/ARE patients, with higher
rates in the more severe phenotypes.4–6 Recently we
reported on patients carrying mutations in RBFOX1/3 and
DEPDC5 genes, although these findings still need to be
reproduced in larger cohorts.7,8
Two other genes that were considered to be associated
with phenotypes of the epilepsy–aphasia spectrum are
ELP4 and SRPX2.9,10 ELP4 (elongator acetyltransferase
complex subunit 4) is part of the multisubunit (ELP1-
ELP6) elongator complex which, among other functions,
was shown to regulate the maturation of cortical projec-
tion neurons.11 Its role in rolandic epilepsy was sug-
gested by a genome-wide linkage scan for the
electroencephalography (EEG) trait of RE–centrotempo-
ral spikes (CTS).9 This study on 38 families (ascertained
through RE index cases) yielded a locus for the CTS
trait at chromosome 11p13, with a maximum logarithm
of the odds (LOD) score of 4.30. Subsequent fine map-
ping revealed an association of three intronic single-
nucleotide polymorphisms (SNPs) within the ELP4 gene.
However, re-sequencing of the coding region of this
gene in a total of 76 patients failed to identify any path-
ogenic variants.9,12
The second candidate gene SRPX2 (sushi-repeat contain-
ing protein X-linked 2) was identified in a French family
with rolandic seizures, orofacial dyspraxia, and mental
retardation fitting our definition of atypical rolandic epi-
lepsy.10 Linkage in this family of seven affected members
led to a ~20 cM region (containing 82 genes) between Xq21
and Xq22 (LOD score 3.01). In a subsequent mutation
search a gain-of-glycosylation variant in the SRPX2 gene
(p.N327S) was identified as the presumed disease-causing
mutation. A follow-up screen in a series of individuals with
related epilepsy disorders (including 81 RE and 27 ARE
patients) revealed a second missense mutation (p.Y72S) in a
patient with RE and bilateral perisylvian polymicrogyria.10
In a different study a splice-site variant (c.961 + 1G>A)
was identified in one male patient with autism spectrum dis-
order.13 The two SRPX2 missense mutations were consid-
ered to cause a misfolding of the secreted protein, with the
p.N327S variant exerting a dominant negative effect and the
p.Y72S variant leading to a loss of protein function.10,12
The relevance of the p.N327S mutation was called into
question once a missense mutation in the GRIN2A gene was
found to cosegregate with the epilepsy phenotype in all and
with verbal dyspraxia in most of the affected individuals in
this family.5
Legitimate doubts were raised for an association of these
two genes with CTS in the context of RE (ELP4) and
respectively with ARE (SRPX2), particularly as no positive
replications have been reported so far and the proposed
pathogenic SRPX2 variants were also found in control
individuals.5,12,14 The purpose of the present study was to
reinvestigate the disease association of these two candidate
genes in a cohort of 280 patients with RE/ARE. We also
gathered indirect evidence by including close interaction
partners of ELP4 and SRPX2 in our search for pathogenic
variants and genomic rearrangements.
Patients and Methods
In total 290 patients of European ancestry diagnosed with
RE (157 male and 98 female) or ARE (19 males and 16
females) according to the international classification were
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recruited in Germany, Austria, and Canada. Two hundred
six patients were ascertained, irrespective of their family
history, and 84 children through multiplex families (one sib-
ling with RE/ARE or CTS was required). One hundred
ninety-six healthy German volunteers (96 male, 100 female)
served as population controls for the association analysis of
ELP4 SNPs, and 403 Austrian population controls (192
male, 211 female) were genotyped for the SRPX2 p.N327S
variant. The study was approved by all respective local
institutional review boards.
Whole exome sequencing for candidate genes analysis
was performed in a subset of 204 patients (RE = 182,
ARE = 22) using the Nimblegen-SeqCapEZ-V2 44M
enrichment kit on the Illumina HiSeq2000 system (Illumina,
Inc., San Diego, CA, U.S.A.). For 280 patients (RE = 248,
ARE = 32) SNP-array genotyping and copy number variant
(CNV) detection was performed on the Illumina OmniEx-
press platform and analyzed with the Illumina Genome
Viewer, PennCNV and PLINK.1.7 software. Genotyping of
the SRPX2 rs121918363 variant (p.N327S) was done with a
TaqMan SNP Genotyping Assay (Life Technologies, Carls-
bad, CA, U.S.A.). For the functional prediction of rare vari-
ants, we employed the dbNSFPv2.3 database (http://sites.
google.com/site/jpopgen/dbNSFP) and for the identification
of SRPX2 and ELP4 interaction partners the STRING tool
(http://string-db.org/ filtered for experimental evidence).
Statistical power was calculated with the online Genetic
power calculator (http://pngu.mgh.harvard.edu/%7Epur-
cell/gpc). The exome variant server (EVS; accessed 12/
2013; http://evs.gs.washington.edu/EVS/) was queried for
the frequency of genetic variants in the respective genes in
the European control population. Further details on patients
and methods can be found in the supporting information.
Results
Elp4
Analyzing the coding sequences of ELP4 in 204 patients
with RE/ARE revealed four missense variants (three known
and one unknown), none of which was predicted as damag-
ing by the dbNSFPv2.3 database (using the LR/RadialSVM
ensemble score, which is composed of 10 widely used com-
ponent scores) (Table S1). The frequency of rare variants
did not differ from the one obtained in European controls of
the EVS; neither did any of the close interaction partners of
ELP4 (ELP2-6, IKBKAP, URM1, SIRT1, PUS3, NFYB,
MED31, MOCS3) show an excess of rare or damaging vari-
ants (Table 1).
Next we replicated the previously reported association of
three intronic SNPs in the ELP4 gene with the CTS trait9 in
280 RE/ARE patients and 196 controls. We genotyped one
SNP (rs986527) directly and the others via proxy SNPs in
high linkage disequilibrium (LD). Although we had a power
of 99% to detect the reported allelic odds ratio (OR); e.g.,
OR 1.88 for rs986527, alpha = 0.05, allelic 1 d.f. test), our
association analysis failed to replicate the initial association
claim (Table 2). We also performed an extended SNP asso-
ciation analysis covering the whole ELP4 gene (as done in
Table 1. Frequency of rare variants in ELP4, SRPX2, and interacting genes in 204 RE/ARE patients and 4,300 European
individuals of the EVS
Gene
RE cases varianta
alleles/total alleles (%)
EVS controls variant
alleles/ total alleles (%) p- Valueb
RE cases damaging
allelesc/total alleles (%)
EVS controls damaging
allelesc/total alleles (%) p- Valueb
ELP4 8/408 (1.96) 161/8,222 (1.96) 1 0/408 (0) 0/8,222 (0) 1
SRPX2 2/285 (0.70) 34/6,728 (0.51) 0.66 0/287 (0) 1/6,728 (0.01) 1
ELP4 interaction partners
ELP2 12/408 (2.94) 259/8,600 (3.01) 1 0/408 (0) 13/8,600 (0.15) 1
ELP3 1/408 (0.25) 37/8,600 (0.43) 1 0/408 (0) 15/8,600 (0.17) 1
ELP5 1/408 (0.25) 16/8,600 (0.19) 0.55 0/408 (0) 1/8,600 (0.01) 1
ELP6 1/408 (0.25) 32/8,352 (0.38) 1 0/408 (0) 0/8,352 (0) 1
IKBKAP 5/408 (1.23) 174/8,600 (2.02) 0.36 0/408 (0) 2/8,600 (0.02) 1
URM1 1/408 (0.25) 12/8,600 (0.14) 0.45 0/408 (0) 6/8,600 (0.07) 1
SIRT1 2/408 (0.49) 75/8,600 (0.87) 0.59 0/408 (0) 0/8,600 (0) 1
PUS3 1/408 (0.25) 137/8,600 (1.59) 0.02 0/408 (0) 12/8,600 (0.14) 1
NFYB 1/408 (0.25) 0/8,600 (0) 0.05 0/408 (0) 0/8,600 (0) 1
MED31 1/408 (0.25) 6/8,600 (0.07) 0.28 0/408 (0) 0/8,600 (0) 1
MOCS3 12/408 (2.94) 121/8,600 (1.41) 0.02 2/408 (0.49) 8/8,600 (0.09) 0.07
SRPX2 interaction partners
ADAMTS4 6/408 (1.47) 204/8,600 (2.37) 0.31 0/408 (0) 11/8,600 (0.13) 1
CTSB 6/408 (1.47) 103/8,600 (1.20) 0.64 3/408 (0.74) 69/8,600 (0.80) 1
PLAUR 4/408 (0.98) 110/8,600 (1.28) 0.82 0/408 (0) 0/8,600 (0) 1
FOXP2 1/408 (0.25) 29/8,600 (0.34) 1 0/408 (0) 13/8,600 (0.15) 1
aRefers to variant alleles (missense, nonsense, splice-site, frameshift variants) with a minor allele frequency <1%.
bFisher’s exact test, gene-specific comparison of variant alleles to all alleles in patients versus controls.
cRefers to the subset of the above missense variants predicted as damaging by dbNSFPV2.3 database. This prediction is based on a 10-component score.
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the screening stage of the original report9), but none of the
10 SNPs tested achieved nominal significance (p > 0.05).
Finally we performed a screen for structural variations in
280 patients covering the genomic region of ELP4 or any of
the other 11 interacting genes and did not find any CNVs
affecting any of the investigated genes.
Srpx2
Next-generation sequencing of SRPX2 exons in 204
patients identified two boys with the previously described
p.N327Smutation in this X chromosomal gene (rs121918363;
c.980A>G; NM_014467.2). Other rare variants were not
detected. Genotyping a further 43 RE/ARE patients for the
p.N327S variant did not reveal additional mutation carriers.
In contrast, we detected one female heterozygous p.N327S
carrier by genotyping 403 Austrian controls and a search for
this mutation in 4,300 European controls (2,428 female,
1,872 male) of the EVS yielded 11 additional individuals (8
heterozygous females, 3 hemizygous males). A statistical
comparison between patients and controls (both sexes) did
not suggest a specific enrichment of this variant among
RE/ARE patients, neither in separate comparison to the
Austrian or the EVS controls (2/247 vs. 1/403 or 11/4300)
nor to the merged European control set (12/4703; Fisher’s
exact test p = 0.15). A subanalysis in males yielded a
borderline significance that was lost after Bonferroni
correction (2/146 male patients vs. 3/2064 male controls
p-(uncorrected) = 0.04). The two patients carrying the
mutation, one diagnosed with typical rolandic epilepsy and
the other one with LKS, share a common haplotype between
chrX:98482335-100213232. For both patients the magnetic
resonance imaging (MRI) scan was normal and the family
history for epilepsy or seizures was negative. None of the
two boys harbors aGRIN2A variation.
We also performed a search for sequence variants in four
genes identified as close SRPX2-interaction partners (AD-
AMTS4, CTSB, PLAUR, FOXP2) in 204 affected individu-
als, without finding any excess of rare or deleterious
variants in comparison to European controls of the EVS
(Table 1). Finally, a SNP-array based screen for structural
variations within the genomic region of the SRPX2 gene and
its four interaction partners in 280 RE/ARE patients did not
reveal any CNVs.
Discussion
Our elaborate reexamination analysis does not support a
major role for ELP4 and SRPX2 genes in RE/ARE.
The main evidence in favor of ELP4 as an underlying
gene for CTS was a linkage peak and the subsequent associ-
ation of three intronic markers within the ELP4 gene in a
study of 38 families with this EEG trait.9 Our failure to rep-
licate the SNP-association analysis (despite having ade-
quate power) suggests that common ELP4 alleles do not
significantly contribute to CTS in the European population.
The lack of deleterious variants and CNVs in ELP4 or its
close interaction partners further questions the role of ELP4
in CTS. However, our data do not exclude that variations in
this gene or its regulatory elements might still be of rele-
vance in odd families.
The claim of SRPX2mutations being pathogenic for ARE
mainly rests on the cosegregation of the p.N327S variant in
a family with ARE, but the later identification of a concomi-
tant co-segregating missense mutation in the GRIN2A ques-
tioned this hypothesis.5 In support of its importance are
subsequent experimental data demonstrating the functional
relevance of the p.N327S variant for cortical development
and epileptogenicity. Significantly, expression of the
mutant N327S-SRPX2 protein leads to an impairment of
neuronal migration resulting in spontaneous epileptiform
activity and in reduced vocalizations in mice.12,15 This last
observation is appealing because alterations in language
development can be part of the phenotypic spectrum of
ARE and because genes interacting with SRPX2 were
associated with language development (FOXP2) or cerebral
lateralization in dyslexia (PCSK6).16–18
Our detection of the p.N327S variant in controls with an
almost similar frequency to affected individuals, argues
against a major pathogenic effect in RE/ARE. We observed
only a suggestive excess in affected boys, although this did
not remain significant after correction. This later phenome-
non would contrast with the dominant negative effect of the
variant, which may lead to functional similarity in both gen-
ders due to the partial use of the mutant gain-of-glycosyla-
tion site.10
One limitation of this study is that the controls were not
specifically screened for the presence of RE/ARE, let alone
milder manifestations such as CTS or minor speech and
behavioral problems. Therefore, we cannot exclude a coin-
cidental accumulation of these phenotypes in the control
groups, which could have blurred the analysis. As no other
sequence or structural variants could be identified for the
SRPX2 gene and no specific enrichment of variants was
observed for SRPX2 interacting partners, our results do not
support a major contribution of this gene to rolandic epi-
lepsy and its atypical variants, although a relevance in odd
families or for related subtle phenotypes cannot be
excluded.
Table 2. ELP4–SNP association results, 280 RE cases
versus 196German controls
SNP Minor allele
Frequency
patients
Frequency
controls p-Value
rs1232186 A 0.420 0.424 0.9
rs986527 T 0.354 0.380 0.4
SNPs reported as associated with CTS (rs986527, rs11031434, rs964112)9
were genotyped directly (rs986527) or via proxy SNPs in high LD (rs986527,
rs964112: r2 = 0.92; rs1232186, rs11031434: r2 = 0.96) in 280 patients with
RE/ARE and 196 German controls.
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